Boardroom Alpha
Boardroom Alpha
SYF · Additional Proxy Materials (DEFA14A) · Filed April 29, 2026

Synchrony Financial — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 29, 2026
Ticker
SYF
Accession
0001601712-26-000019
Boardroom Alpha · Filing insights

Synchrony Financial's board recommends voting For all nominees, KPMG ratification, and the executive compensation advisory.

About Synchrony Financial
Market cap
$25.4B
1Y TSR
+11.9%
3Y TSR
+36.1%
Board grade
B-
Sector
Financial Services
CEO
Brian D Doubles
Last annual meeting: Jun 24, 2026 · View full Synchrony Financial profile →
defa14a
Your Vote Counts! Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V94550-P49055 *Please check the meeting materials for any special requirements for meeting attendance. SYNCHRONY FINANCIAL 777 LONG RIDGE ROAD STAMFORD, CT 06902 SYNCHRONY FINANCIAL 2026 Annual Meeting Vote by June 23, 2026 11:59 PM ET You invested in SYNCHRONY FINANCIAL and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 24, 2026. Vote Virtually at the Meeting* June 24, 2026 9:00 a.m., Eastern Time Virtually at: www.virtualshareholdermeeting.com/SYF2026 Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 10, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.


 
Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V94551-P49055 THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. 1. Election of Directors Nominees: 1a. Brian D. Doubles For 1b. Fernando Aguirre For 1c. Paget L. Alves For 1d. Kamila Chytil For 1e. Daniel Colao For 1f. Arthur W. Coviello, Jr. For 1g. Deborah Ellinger For 1h. Roy A. Guthrie For 1i. Jeffrey G. Naylor For 1j. Bill Parker For 1k. Laurel J. Richie For 1l. Ellen M. Zane For 2. Ratification of Selection of KPMG LLP as Independent Registered Public Accounting Firm of the Company for 2026. For 3. Advisory Vote to Approve Named Executive Officer Compensation. For NOTE: All shares will be voted as instructed. In the absence of instructions, all shares will be voted with respect to registered stockholders that return a signed proxy card, in accordance with the Board of Directors recommendations. In their discretion, the proxies are authorized to vote upon any other matter as may properly be presented at the meeting or any adjournments or postponements thereof.


 
From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Synchrony Financial (SYF)

Reference

Frequently asked questions

When did Synchrony Financial file this DEFA14A?
Synchrony Financial (SYF) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 29, 2026. The accession number assigned by EDGAR is 0001601712-26-000019.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
Synchrony Financial's board recommends voting For all nominees, KPMG ratification, and the executive compensation advisory. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Synchrony Financial's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Synchrony Financial has filed under CIK 1601712, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer